KR100811927B1 - 카복사미딘 변형된 모노사이클릭 염기를 함유하는누클레오시드 유사체 - Google Patents

카복사미딘 변형된 모노사이클릭 염기를 함유하는누클레오시드 유사체 Download PDF

Info

Publication number
KR100811927B1
KR100811927B1 KR1020027010417A KR20027010417A KR100811927B1 KR 100811927 B1 KR100811927 B1 KR 100811927B1 KR 1020027010417 A KR1020027010417 A KR 1020027010417A KR 20027010417 A KR20027010417 A KR 20027010417A KR 100811927 B1 KR100811927 B1 KR 100811927B1
Authority
KR
South Korea
Prior art keywords
type
compounds
cells
pharmaceutical composition
carboxamidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027010417A
Other languages
English (en)
Korean (ko)
Other versions
KR20030032917A (ko
Inventor
로버트 탐
칸다 라마사미
찌 홍
존슨 라우
Original Assignee
리버팜 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리버팜 인크. filed Critical 리버팜 인크.
Publication of KR20030032917A publication Critical patent/KR20030032917A/ko
Application granted granted Critical
Publication of KR100811927B1 publication Critical patent/KR100811927B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
KR1020027010417A 2000-02-15 2001-02-15 카복사미딘 변형된 모노사이클릭 염기를 함유하는누클레오시드 유사체 Expired - Fee Related KR100811927B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18267600P 2000-02-15 2000-02-15
US60/182,676 2000-02-15
US09/595,365 2000-06-16
US09/595,365 US6455508B1 (en) 2000-02-15 2000-10-05 Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
PCT/US2001/040148 WO2001060379A1 (en) 2000-02-15 2001-02-15 Nucleoside analogs with carboxamidine modified monocyclic base
PCT/US2001/005172 WO2001060381A1 (en) 2000-02-15 2001-02-15 Nucleoside analogs with carboxamidine-modified bicyclic base

Publications (2)

Publication Number Publication Date
KR20030032917A KR20030032917A (ko) 2003-04-26
KR100811927B1 true KR100811927B1 (ko) 2008-03-10

Family

ID=26878297

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020027010417A Expired - Fee Related KR100811927B1 (ko) 2000-02-15 2001-02-15 카복사미딘 변형된 모노사이클릭 염기를 함유하는누클레오시드 유사체
KR1020027010593A Withdrawn KR20030005190A (ko) 2000-02-15 2001-02-15 카르복사미딘-개질된 바이시클릭 염기를 지닌뉴클레오시드 유사체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020027010593A Withdrawn KR20030005190A (ko) 2000-02-15 2001-02-15 카르복사미딘-개질된 바이시클릭 염기를 지닌뉴클레오시드 유사체

Country Status (28)

Country Link
US (1) US6455508B1 (enExample)
EP (3) EP1257281B8 (enExample)
JP (3) JP2004510691A (enExample)
KR (2) KR100811927B1 (enExample)
CN (2) CN1268335C (enExample)
AT (1) ATE377422T1 (enExample)
AU (2) AU3845001A (enExample)
BR (2) BR0108401A (enExample)
CA (2) CA2399208C (enExample)
CY (1) CY1107103T1 (enExample)
CZ (2) CZ20022799A3 (enExample)
DE (1) DE60131250T8 (enExample)
DK (1) DK1257281T3 (enExample)
ES (2) ES2295148T3 (enExample)
HR (2) HRP20020583A2 (enExample)
HU (2) HUP0300912A2 (enExample)
IL (3) IL150555A0 (enExample)
MX (2) MXPA02007931A (enExample)
NO (2) NO329927B1 (enExample)
NZ (2) NZ521390A (enExample)
PL (2) PL365239A1 (enExample)
PT (1) PT1257281E (enExample)
RS (1) RS20090086A (enExample)
RU (2) RU2002120483A (enExample)
SI (2) SI21077A (enExample)
SK (2) SK11572002A3 (enExample)
WO (2) WO2001060379A1 (enExample)
YU (1) YU61502A (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
US7056895B2 (en) * 2000-02-15 2006-06-06 Valeant Pharmaceuticals International Tirazole nucleoside analogs and methods for using same
US7638496B2 (en) * 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AU2001272923A1 (en) 2000-05-26 2001-12-11 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
JP2004532184A (ja) 2001-01-22 2004-10-21 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
WO2003037908A1 (en) * 2001-10-31 2003-05-08 Ribapharm Inc. Antiviral combination therapy and compositions
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN1849142A (zh) 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2′－支链核苷和黄病毒突变
KR20050109918A (ko) 2002-12-12 2005-11-22 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드의 제조 방법
RU2005133093A (ru) * 2003-03-28 2006-07-27 Фармассет, Инк. (Us) Соединения для лечения флавивирусных инфекций
US20040197287A1 (en) * 2003-04-04 2004-10-07 The Procter & Gamble Company Personal care composition containing an antidandruff component and a nonionic surfactant
US20040202636A1 (en) * 2003-04-11 2004-10-14 Kaczvinsky Joseph Robert Personal care composition containing an antidandruff component and a nonionic surfactant
US20040197292A1 (en) * 2003-04-04 2004-10-07 The Procter & Gamble Company Personal care composition containing an antidandruff component and a nonionic surfactant
US20050009848A1 (en) * 2003-07-10 2005-01-13 Icn Pharmaceuticals Switzerland Ltd. Use of antivirals against inflammatory bowel diseases
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
US20050095218A1 (en) * 2003-10-29 2005-05-05 The Procter & Gamble Company Personal care composition containing a detersive surfactant, an antidandruff component, and ketoamide surfactants
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
US7534767B2 (en) 2004-06-15 2009-05-19 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
US7879797B2 (en) 2005-05-02 2011-02-01 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
AU2006275605B2 (en) 2005-08-01 2011-01-06 Merck Sharp & Dohme Corp. Macrocyclic peptides as HCV NS3 protease inhibitors
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
AU2006342447B2 (en) * 2005-12-28 2013-06-20 Translational Therapeutics, Inc Translational dysfunction based therapeutics
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
CA2667165A1 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
JP5345941B2 (ja) 2006-10-24 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
CA2667146C (en) 2006-10-24 2016-01-19 Merck & Co., Inc. Hcv ns3 protease inhibitors
ES2444575T3 (es) 2006-10-27 2014-02-25 Merck Sharp & Dohme Corp. Inhibidores de la proteasa NS3 del VHC
US20100099695A1 (en) 2006-10-27 2010-04-22 Liverton Nigel J HCV NS3 Protease Inhibitors
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2010513450A (ja) 2006-12-20 2010-04-30 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス性インドール
CN101754970B (zh) 2007-07-17 2013-07-10 P.安杰莱蒂分子生物学研究所 用于治疗丙型肝炎的大环吲哚衍生物
WO2009010804A1 (en) 2007-07-19 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic compounds as antiviral agents
US8461107B2 (en) 2008-04-28 2013-06-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
SI2310095T1 (sl) 2008-07-22 2013-01-31 Merck Sharp & Dohme Corp. Makrocikliäśne kuinoksalinske spojine kot hcv ns3 proteazni inhibitorji
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
WO2013074386A2 (en) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
WO2013106344A1 (en) 2012-01-12 2013-07-18 Ligand Pharmaceuticals, Inc. 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
CN102978264B (zh) * 2012-11-14 2014-12-10 广东肇庆星湖生物科技股份有限公司 一种他立韦林的制备方法
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
EP3623364A1 (en) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
US9708359B2 (en) 2015-08-06 2017-07-18 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof
ES3011607T3 (en) 2017-09-21 2025-04-07 Chimerix Inc Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7h-pyrrolo(2,3-d)pyrimidine-5-carboxamide and uses thereof
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991078A (en) 1971-06-01 1976-11-09 Icn Pharmaceuticals, Inc. N-substituted 1,2,4-triazoles
US3984396A (en) 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US3962211A (en) * 1975-01-13 1976-06-08 The University Of Utah 7-substituted nucleoside compounds
US4093624A (en) 1977-01-31 1978-06-06 Icn Pharmaceuticals, Inc. 1,2,4-Thiadiazolidine-3,5-dione
SU1124559A1 (ru) * 1983-06-08 1986-07-07 Институт молекулярной биологии АН СССР 1-(2-Оксиэтоксиметил)-1,2,4-триазол-5-карбоксамид,обладающий активностью противвируса герпеса
JPS6426593A (en) 1987-07-21 1989-01-27 Asahi Glass Co Ltd Nucleoside derivative
US4892865A (en) * 1987-12-01 1990-01-09 The Regents Of The University Of Michigan Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
US5405837A (en) * 1993-05-18 1995-04-11 Indiana University Foundation Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
RU2186569C2 (ru) * 1996-01-23 2002-08-10 Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ Модуляция экспрессии тн1/тн2 цитокинов рибавирином и аналогами рибавирина в активированных т-лимфоцитах
CA2267279A1 (en) * 1996-10-16 1998-04-23 Devron Averett Monocyclic l-nucleosides, analogs and uses thereof
MXPA02001753A (es) * 1999-08-27 2002-10-23 Ribapharm Inc Analogos de nucleosido de pirrolo [2,3-d]pirimidina.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem., Vol.35:3231-3238(1992.)

Also Published As

Publication number Publication date
PL200140B1 (pl) 2008-12-31
RU2259831C2 (ru) 2005-09-10
NZ520877A (en) 2004-12-24
AU783142B2 (en) 2005-09-29
ES2528429T9 (es) 2015-05-07
CN1438891A (zh) 2003-08-27
EP1813278B9 (en) 2015-04-01
DE60131250T8 (de) 2009-01-15
EP1257281A4 (en) 2003-03-19
HU229480B1 (en) 2014-01-28
IL150555A0 (en) 2003-02-12
AU3845001A (en) 2001-08-27
HUP0300027A2 (en) 2003-05-28
NO20023855D0 (no) 2002-08-14
SK11492002A3 (sk) 2003-02-04
SI21077A (sl) 2003-06-30
BR0108402A (pt) 2003-03-11
CA2395854A1 (en) 2001-08-23
JP4975930B2 (ja) 2012-07-11
EP1278528A1 (en) 2003-01-29
DE60131250T2 (de) 2008-08-28
EP1257281A1 (en) 2002-11-20
SK11572002A3 (sk) 2003-02-04
NZ521390A (en) 2004-05-28
WO2001060381B1 (en) 2001-11-01
NO20023852L (no) 2002-10-09
EP1813278B1 (en) 2014-10-29
NO329927B1 (no) 2011-01-24
EP1257281B1 (en) 2007-11-07
JP2004509061A (ja) 2004-03-25
AU4798801A (en) 2001-08-27
ATE377422T1 (de) 2007-11-15
CN1268335C (zh) 2006-08-09
HRP20020583A2 (en) 2005-10-31
DE60131250D1 (de) 2007-12-20
PT1257281E (pt) 2007-12-11
HUP0300027A3 (en) 2003-09-29
CA2399208A1 (en) 2001-08-23
JP5253204B2 (ja) 2013-07-31
KR20030005190A (ko) 2003-01-17
CY1107103T1 (el) 2012-10-24
EP1257281B8 (en) 2008-01-23
NO20023855L (no) 2002-10-08
BR0108401A (pt) 2004-01-06
US6455508B1 (en) 2002-09-24
NO20023852D0 (no) 2002-08-14
RS20090086A (sr) 2010-06-30
RU2002120483A (ru) 2004-01-27
EP1813278A1 (en) 2007-08-01
JP2009102406A (ja) 2009-05-14
KR20030032917A (ko) 2003-04-26
WO2001060381A1 (en) 2001-08-23
CN1420779A (zh) 2003-05-28
HUP0300912A2 (hu) 2003-08-28
IL150990A0 (en) 2003-02-12
PL357945A1 (en) 2004-08-09
ES2528429T3 (es) 2015-02-09
CA2399208C (en) 2010-04-13
RU2002120922A (ru) 2004-01-27
SK287765B6 (sk) 2011-09-05
HRP20020657A2 (en) 2005-10-31
MXPA02007932A (es) 2004-10-15
IL150990A (en) 2009-05-04
CZ20022799A3 (cs) 2003-09-17
CZ20022798A3 (cs) 2003-03-12
DK1257281T3 (da) 2008-01-14
MXPA02007931A (es) 2004-10-15
YU61502A (sh) 2006-03-03
ES2295148T3 (es) 2008-04-16
HK1051149A1 (en) 2003-07-25
WO2001060379A1 (en) 2001-08-23
JP2004510691A (ja) 2004-04-08
SI21076A (sl) 2003-06-30
CZ302327B6 (cs) 2011-03-16
EP1278528A4 (en) 2003-03-19
PL365239A1 (en) 2004-12-27

Similar Documents

Publication Publication Date Title
KR100811927B1 (ko) 카복사미딘 변형된 모노사이클릭 염기를 함유하는누클레오시드 유사체
US6815542B2 (en) Nucleoside compounds and uses thereof
EP1027359B1 (en) Monocyclic l-nucleosides, analogs and uses thereof
US20090176721A1 (en) Nucleoside analogs with carboxamidine modified monocyclic base
EP1132393B1 (en) L-Ribavirin and uses thereof
HK1051149B (en) Nucleoside analogs with carboxamidine modified monocyclic base
ZA200206468B (en) Nucleoside analogs with carboxamidine modified monocyclic base.
HK1028977B (en) Monocyclic l-nucleosides, analogs and uses thereof
HK1038365B (en) L-ribavirin and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P18-X000 Priority claim added or amended

St.27 status event code: A-2-2-P10-P18-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20130821

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20140305

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20150225

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20171228

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190304

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190304